CorMedix director granted 30,453 RSUs

CorMedix Inc. director Duncan Gregory Scott received a grant of 30,453 restricted stock units (RSUs) of common stock on January 26, 2026.

Rhea-AI Filing Summary

CorMedix Inc. director Duncan Gregory Scott received a grant of 30,453 restricted stock units (RSUs) of common stock on January 26, 2026. The RSUs were awarded at a price of $0.00 per unit, reflecting an equity compensation grant rather than a market purchase.

Each RSU represents the right to receive one share of CorMedix common stock. The RSUs will vest in full on January 26, 2027, provided Scott continues his service through the vesting date. After this grant, he beneficially owns 68,786 shares of CorMedix common stock in direct ownership form.

Insider Trade Summary

Grant/Award: 30,453 shares

Grant/Award 1 txn

Insider Duncan Gregory Scott

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	30,453	$0.00	$0.00

Holdings After Transaction: Common Stock — 68,786 shares (Direct)

Footnotes (1)

1. F1. These shares represent restricted stock units issued on January 26, 2026. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. These restricted stock units will vest in full on January 26, 2027, subject to continued service on the vesting date.

FAQ

What equity award did CorMedix Inc. (CRMD) director Duncan Gregory Scott receive?

CorMedix director Duncan Gregory Scott received 30,453 restricted stock units. Each unit represents one share of common stock. The grant was reported at a price of $0.00 per unit as part of his director equity compensation.

When do Duncan Gregory Scott’s CorMedix (CRMD) restricted stock units vest?

The 30,453 restricted stock units granted to Duncan Gregory Scott vest in full on January 26, 2027. Vesting is conditioned on his continued service with CorMedix Inc. through the vesting date.

How many CorMedix (CRMD) shares does Duncan Gregory Scott own after this Form 4 transaction?

Following the RSU grant, Duncan Gregory Scott beneficially owns 68,786 shares of CorMedix common stock. This figure reflects his direct ownership reported after the January 26, 2026 equity award.

Was cash paid for the CorMedix (CRMD) shares reported in this Form 4?

No cash was paid for the shares reported. The 30,453 units were granted at a price of $0.00 per share, indicating they are restricted stock units issued as compensation rather than purchased in the market.

What does the CorMedix (CRMD) Form 4 say about the nature of the reported security?

The filing states the award is composed of restricted stock units. Each restricted stock unit gives the right to receive one share of CorMedix Inc. common stock upon vesting, subject to continued service through January 26, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/27/2026 - 09:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Duncan Gregory Scott

(Last) (First) (Middle)

C/O CORMEDIX INC.

389 INTERPACE PKWY, SUITE 450

(Street)

PARSIPPANY NJ 07054

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc. [ CRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/26/2026		A		30,453	A	$0.00(1)	68,786	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares represent restricted stock units issued on January 26, 2026. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. These restricted stock units will vest in full on January 26, 2027, subject to continued service on the vesting date.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Beth Zelnick Kaufman, attorney-in-fact	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.